Follow
About Jack
Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Montano as cardiovascular biotherapeutics' chief scientific officer. Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.
Jack's Videos
A presentation discussing the possibility of using Intranasally-delivered FGF-1 to treat Parkinson's Disease. This presentation will be using data and information from our most recent medical research study conducted in humans in May 2022.
Jack Jacobs
HEALTHCARE
30:43
Human FGF-1 is a potent growth factor that has been shown to stimulate the growth of new blood vessels, as well as new neurons, in animal models of Parkinson's disease and other brain disorders. In this talk, this previous research will be reviewed, as well as the presentation of late-breaking results from a just completed first human study examining the intranasal delivery of FGF-1 to subjects with Parkinson's disease.
Jack Jacobs
HEALTHCARE
30:39
Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.
Jack Jacobs
BIOTECH
31:30
Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.
Jack Jacobs
BIOTECH
33:04
